An interventional study of Personalized Oral Nutritional Supplementation and Personalized Parenteral Nutritional Supplementation in Colorectal Cancer (Diagnosis) and Malnutrition or Risk of Malnutrition, sponsored by Xiaoqin Luo. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-28.
Sponsored by Xiaoqin Luo · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,139 studies in Colorectal Neoplasms with a site in China — 529 open to participants now, 606 under way, 67 of them phase 3. Colorectal Neoplasms · China.
Among the 1,139 studies in Colorectal Neoplasms with a site in China, this one is the 129th largest by planned enrollment of the 894 interventional ones that give a count, is one of 157 that started in 2024, is one of 150 with no phase, reaches primary completion later than 570 of the 605 other live ones, and was the 941st registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →529 of the 1,139 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:
Full-Life Technologies UK Limited · Sites in China, United States, Australia
Ages 18+
Fudan University · Sites in China
Ages 18–75
Fudan University · Sites in China
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80 · Healthy volunteers
Shanghai EpimAb Biotherapeutics Co., Ltd. · Sites in China
Ages 18–74
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 225 · Phase 2 470 · Phase 3 147 · Phase 4 21
First in 1993; this study’s year is marked. 157 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 80 across the 894 interventional studies, 400 across the 243 observational. Of the 215 that completed or were terminated, 27 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
248 of 1,139 have an industry lead sponsor. The 10 most frequent:
Xiaoqin Luo is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Xiaoqin Luo has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
142 of the studies in Colorectal Neoplasms with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06008119Phase 3Shanghai Kechow Pharma, Inc.Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | 2026-12-24 |
| NCT05171660Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityCombination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer | 2026-12-30 |
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT06280495Phase 3Sun Yat-sen UniversityNeoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | 2026-12-31 |
| NCT05086614Phase 3Fudan UniversityThymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer | 2027-03-31 |
Add all 142 to your calendar (.ics) → With an account.
Among the 1,139 studies in Colorectal Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical study aims to evaluate whether short-term personalized nutritional support, when combined with structured health education, can improve nutritional status, quality of life, and clinical outcomes in patients who have undergone surgery for colorectal cancer (CRC). Colorectal cancer is one of the most common cancers worldwide, and many patients experience malnutrition and poor physical condition during treatment, which can negatively affect recovery and long-term survival.
In this multicenter, randomized, controlled clinical trial, approximately 360 postoperative CRC patients will be enrolled and randomly assigned to one of four groups: (A) nutritional enhancement combined with health education, (B) health education alone, (C) nutritional enhancement alone, or (D) standard care (control group). Nutritional support will include individualized diet counseling and oral nutritional supplements tailored to each patient's needs. Health education will be delivered using an "Internet Plus" approach, including weekly educational videos and expert consultations focusing on nutrition, physical activity, and mental health.
The primary objectives are to determine whether these interventions can improve patients' short-term nutritional status and quality of life. Secondary outcomes include the impact of interventions on long-term survival, treatment-related side effects, patient adherence to nutrition recommendations, and psychological well-being.
This study will also investigate the biological mechanisms underlying the clinical effects by analyzing changes in the gut microbiome, blood-based metabolic profiles, and immune responses. Blood, stool, and tumor tissue samples will be collected and analyzed using advanced techniques, including untargeted metabolomics, metagenomics, and single-cell sequencing.
This trial is designed to provide evidence for the integration of nutritional strategies into routine cancer care, and to guide the development of more personalized, effective nutrition-based therapies for colorectal cancer patients. Participants will be followed for up to annually up to 5 years to evaluate both clinical outcomes and biological markers of response.
This is a prospective, multicenter, open-label, randomized controlled clinical trial designed to assess the effects and underlying mechanisms of short-term nutritional enhancement combined with health education on clinical outcomes in patients undergoing surgery for non-metastatic colorectal cancer (stages IIa, IIb, IIIa). The rationale is based on the high prevalence of malnutrition among CRC patients, which significantly impacts treatment tolerance, quality of life, and long-term prognosis.
Eligible participants will be randomized into four parallel arms: (1) individualized nutritional enhancement plus structured health education; (2) structured health education alone; (3) individualized nutritional enhancement alone; and (4) standard care without additional intervention. Personalized nutrition plans will be developed based on energy and protein needs, supported by dietary counseling and the provision of oral nutritional supplements. Health education will be delivered through a digital platform, featuring weekly videos and interactive content on nutrition, exercise, and psychological well-being.
The study includes a 14-day intervention phase and a 12-month follow-up period. Outcomes will be assessed at baseline, and at 1, 2, 3, 6, and 12 months, and annually up to 5 years to evaluate both clinical outcomes and biological markers of response.post-intervention. Key endpoints include improvements in nutritional status, patient-reported quality of life, and overall survival metrics.
To investigate mechanisms, the study incorporates biological sampling and multi-omics analysis. Non-targeted serum metabolomics, gut microbiota metagenomics, and single-cell RNA sequencing of tumor and adjacent normal tissues will be used to characterize metabolic and immune changes associated with the interventions. The study also evaluates the role of inflammatory markers and immune cell profiles in mediating clinical effects.
This trial is expected to generate high-quality evidence supporting the integration of nutrition and health education strategies into standard postoperative care for CRC patients. It may also identify novel metabolic or microbial biomarkers associated with treatment response and prognosis, contributing to the development of precision nutrition approaches in oncology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive individualized nutritional enhancement along with structured health education. Nutritional intervention includes personalized dietary plans and oral nutritional supplements based on energy and protein requirements. Health education is delivered via an "Internet Plus" platform and includes weekly videos and interactive content focusing on nutrition, physical activity, and psychological support. The intervention lasts for 14 days and is followed by a 12-month, and annually up to 5 years to evaluate both clinical outcomes and biological markers of response. follow-up period.
Dietary Supplement: Personalized Oral Nutritional Supplementation · Drug: Personalized Parenteral Nutritional Supplementation · Behavioral: Structured Nutrition-Focused Health Education
Participants in this arm will receive structured health education without additional nutritional supplementation. The education is delivered via an "Internet Plus" platform, including weekly videos and interactive content focused on nutrition knowledge, physical activity guidance, and psychological support. This intervention is administered for 14 days, followed by a 12-month follow-up and annually up to 5 years.
Behavioral: Structured Nutrition-Focused Health Education
Participants in this arm will receive individualized nutritional enhancement based on personalized dietary assessment and calculated energy and protein needs. Interventions include oral nutritional supplements and tailored dietary counseling provided by a clinical nutrition team. No additional health education is provided. The intervention phase lasts for 14 days, with scheduled follow-up for 12 months and annually up to 5 years.
Dietary Supplement: Personalized Oral Nutritional Supplementation · Drug: Personalized Parenteral Nutritional Supplementation
Participants in this arm will receive standard inpatient care without structured nutritional intervention or health education. Patients eat according to personal ability and appetite but do not receive individualized nutrition counseling or supplemental nutrition support. This group serves as the control group for comparison. Routine clinical follow-up will be conducted for 12 months and annually up to 5 years.
Participants receive individualized oral nutritional supplementation based on energy and protein requirements, calculated using the Harris-Benedict equation and body weight (1.2-1.5 g protein/kg/day). The supplement may include complete nutrition powder, whey protein powder, and compound multivitamins. The intervention is prescribed and monitored by a clinical nutrition team and adjusted every 3 days during the 14-day intervention phase. The goal is to ensure both energy and protein intake targets are met. Supplements are administered in addition to standard meals.
Also known as: ONS
For participants unable to meet nutritional goals through oral intake, parenteral nutrition is administered intravenously. The formulation includes amino acids, glucose, lipids, electrolytes, trace elements, and vitamins. Dosages are aligned with those of the enteral nutrition group, ensuring a consistent intake of energy and protein (1.2-1.5 g/kg/day protein). Formulation and administration follow standardized hospital protocols and are supervised by the nutrition support team.
Also known as: PN
Participants receive structured health education focused on nutrition, physical activity, and psychological well-being. The education is delivered over 14 days using a digital "Internet Plus" platform, featuring weekly videos, interactive Q\&A sessions, and guidance from a multidisciplinary nutrition support team. Educational content covers dietary recommendations, exercise safety, stress management, and post-treatment recovery strategies. Materials are updated weekly, and participants may access them remotely via smartphone or tablet. This intervention aims to improve nutrition knowledge, adherence, and health behavior change.
Also known as: Internet-Based Health Education, Multimedia Health Literacy Intervention
Change in Nutritional Status Assessed by Modified Patient-Generated Subjective Global Assessment (mPG-SGA)
Longitudinal assessment of nutritional status using the mPG-SGA, a validated tool composed of five sections (weight loss history, dietary intake, symptoms, function/activity, and age). Total scores range from 0 to ≥7 points, with higher scores indicating worse nutritional status. Patients will be classified as: 0-2 = Normal 3-6 = Mild malnutrition ≥7 = Moderate to severe malnutrition.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Change in Global Health Status Score on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Assessment of patients' perceived overall health status using the global health subscale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scores range from 0 to 100, with higher scores indicating better global quality of life.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Change in Symptom Scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Assessment of symptom burden including fatigue, pain, nausea/vomiting, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulty using symptom subscales of the EORTC QLQ-C30. Each symptom is scored separately from 0 to 100, with higher scores indicating worse symptom severity.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Overall Survival (OS) in Cancer Patients
Overall survival is defined as the time from the date of enrollment to the date of death from any cause. Patients still alive at the last follow-up will be censored. Kaplan-Meier survival analysis and Cox proportional hazards regression will be used to estimate survival and explore associations with baseline and longitudinal nutritional status.
Time frame: From date of enrollment until death or last follow-up (up to 5 years)
Progression-Free Survival (PFS) in Cancer Patients
Progression-free survival is defined as the time from enrollment to the first documented disease progression or death from any cause, whichever occurs first. Patients without progression at the time of last follow-up will be censored. PFS will be analyzed using Kaplan-Meier estimates and Cox regression models, stratified by nutritional status.
Time frame: From date of enrollment until death or last follow-up (up to 5 years)
Change in Nutritional Risk Assessed by Nutritional Risk Screening 2002 (NRS-2002)
Longitudinal evaluation of nutritional risk using the NRS-2002, which considers disease severity, nutritional impairment, and age. Total score ranges from 0 to ≥7 points. A score of ≥3 indicates nutritional risk and warrants intervention; \<3 indicates no immediate risk.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Serum Total Protein
Serum total protein concentration (g/L), used to evaluate protein-energy nutritional status. Measured using standard biochemical assays.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Serum Albumin
Serum albumin concentration (g/L), used to assess visceral protein status and systemic inflammation.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Serum Prealbumin
Serum prealbumin level (mg/L), an indicator of short-term changes in protein-energy nutritional status.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Serum Transferrin
Serum transferrin concentration (g/L), a marker of protein status and iron metabolism.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
C-Reactive Protein (CRP)
Serum CRP (mg/L), a marker of systemic inflammation and acute-phase response.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Blood Glucose
Fasting blood glucose (mmol/L), measured to assess metabolic function and risk of hyperglycemia.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Aspartate Aminotransferase (AST)
AST concentration (U/L), used as a liver function test and hepatotoxicity marker.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Alanine Aminotransferase (ALT)
ALT level (U/L), a liver enzyme measured to monitor hepatic injury.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Interleukin-1 (IL-1)
IL-1 concentration (pg/mL), a pro-inflammatory cytokine indicative of immune and inflammatory activity.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Tumor Necrosis Factor-alpha (TNF-α)
Tumor Necrosis Factor-alpha (TNF-α) level (pg/mL) measured to assess systemic inflammation and cancer-related cachexia.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Serum Creatinine
Serum creatinine (μmol/L), measured to evaluate kidney function and treatment-related nephrotoxicity.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Blood Urea Nitrogen
Blood urea nitrogen (umol/L), used to monitor renal function and protein catabolism.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Total Bilirubin
Blood urea nitrogen (umol/L), used to monitor renal function and protein catabolism.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Total Cholesterol
Total cholesterol level (mmol/L), measured to assess lipid metabolism and nutritional status.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Triglycerides
Serum triglyceride level (mmol/L), used to evaluate energy reserves and lipid metabolism.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
High-Density Lipoprotein Cholesterol (HDL-C)
HDL-C (mmol/L), assessed as a marker of cardiovascular health and lipid status.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Low-Density Lipoprotein Cholesterol (LDL-C)
LDL-C (mmol/L), measured as a risk factor for cardiovascular disease and lipid status.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Interleukin-6 (IL-6)
IL-6 level (pg/mL), a pro-inflammatory cytokine measured to monitor systemic inflammation and cachexia.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Hemoglobin
Hemoglobin concentration (\*10⁹/L), used to assess anemia and oxygen-carrying capacity.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
White Blood Cell Count (Leukocytes)
Total white blood cell count (\*10⁹/L), measured to monitor immune status and detect infection or myelosuppression.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Neutrophil Count
Absolute neutrophil count (\*10⁹/L), used to assess infection risk and bone marrow suppression.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Lymphocyte Count
Lymphocyte count (\*10⁹/L), measured to evaluate immune competence.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Red Blood Cell Count
Red blood cell count (\*10¹²/L), used to assess erythropoiesis and anemia.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Platelet Count
Platelet count (\*10⁹/L), measured to evaluate coagulation status and myelosuppression.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Height
Standing height (cm) measured using a stadiometer with 0.5 cm precision. Values adjusted for presence of ascites, edema, or large tumors.ascites, systemic edema, and huge tumors.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Body Weight
Body weight (kg) measured using a calibrated scale with 0.2 kg precision. Values adjusted if ascites or edema are present.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Body Mass Index (BMI)
BMI calculated as weight (kg) divided by height squared (m²), recorded to one decimal place.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Change in Anxiety Symptoms Assessed by Hospital Anxiety and Depression Scale (HADS-A)
Assessment of anxiety using the HADS-A subscale of the Hospital Anxiety and Depression Scale. Scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms. Results will be analyzed in relation to nutritional status (normal, mild, moderate malnutrition).
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Change in Depression Symptoms Assessed by Hospital Anxiety and Depression Scale (HADS-D)
Assessment of depressive symptoms using the HADS-D subscale of the Hospital Anxiety and Depression Scale. Scores range from 0 to 21, with higher scores indicating more severe depression. Results will be analyzed in relation to nutritional status (normal, mild, moderate malnutrition).
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Functional Performance Measured by Karnofsky Performance Status (KPS)
Functional performance will be evaluated using the Karnofsky Performance Status (KPS) scale, which ranges from 0 to 100. Higher scores indicate better functional ability and independence in daily activities. Longitudinal KPS changes will be assessed in relation to changes in nutritional status over time.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Changes in Sleep Quality Assessed by Pittsburgh Sleep Quality Index (PSQI)
Sleep quality and disturbances will be evaluated using the Pittsburgh Sleep Quality Index (PSQI), a standardized questionnaire assessing seven components of sleep. Total scores range from 0 to 21, with higher scores indicating poorer sleep quality. PSQI scores will be analyzed in relation to nutritional risk categories and treatment phases.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Changes in Physical Activity Level During Cancer Treatment
Assessment of leisure-time physical activity levels (mild, moderate, vigorous) and their relationship with nutritional status and cancer treatment response.
Time frame: Baseline, after the intervention, 1, 2, 3, 6, and 12 months after intervention; annually up to 5 years
Changes in Nutrition-Related Knowledge, Attitudes, and Practices (KAP)
Patients' dietary knowledge, attitudes, and practices will be assessed using a validated Nutrition KAP (Knowledge, Attitude, and Practice) questionnaire. The total score ranges from 0 to 104, with higher scores indicating better nutritional knowledge, more positive attitudes, and healthier dietary behaviors. Longitudinal changes in KAP scores will be evaluated in relation to treatment outcomes.
Time frame: Baseline, after the intervention, 6 months after intervention; annually up to 5 years
Healthcare Utilization and Cost of Nutrition-Related Care
Evaluation of healthcare utilization related to nutritional care, including total number of hospitalization days, number of ICU admissions, and direct costs associated with enteral and parenteral nutrition support. Metrics will be analyzed in relation to malnutrition risk at baseline and during treatment.
Time frame: From admission through 30-day post-discharge and annually for 5 years
Incidence of Serious Adverse Events Related to Nutrition or Treatment
Tracking of serious adverse events potentially related to nutritional support or treatment, including infections, allergic reactions, gastrointestinal distress, and metabolic complications.
Time frame: Continuously from enrollment through end of study follow-up (up to 5 years)
Predictive Value of Baseline Nutritional Indicators for 30-Day Clinical Events
Evaluation of whether baseline nutritional indicators-including mPG-SGA scores and laboratory biomarkers such as albumin, prealbumin, and CRP-predict 30-day clinical outcomes, including mortality, ICU admission, and significant unintentional weight loss (\>5%). Logistic regression will be used for model construction and discrimination.
Time frame: Baseline to 30 days post-admission
Nutritional Trajectory Typing and Clustering
Identification of distinct nutritional change trajectories over time using latent class growth analysis (LCGA) and hierarchical clustering based on serial measurements of mPG-SGA and anthropometric data. Trajectories will be used to classify patients into nutritional risk subgroups.
Time frame: From baseline to 12-month follow-up
Agreement Between Nutritional Screening Tools (mPG-SGA vs. NRS-2002)
Assessment of the diagnostic agreement, sensitivity, and specificity of two nutritional screening tools-modified Patient-Generated Subjective Global Assessment (mPG-SGA) and Nutritional Risk Screening 2002 (NRS-2002)-in detecting malnutrition risk. Agreement will be evaluated using Cohen's kappa and ROC curve analysis.
Time frame: Baseline and each scheduled follow-up (up to 5 years)
Sociodemographic Determinants of Malnutrition
Analysis of sociodemographic factors-including income level, education, employment status, and rural vs. urban residence-in predicting baseline malnutrition and nutritional deterioration over time. Multivariable models will be used to explore independent associations.
Time frame: From baseline throughout study follow-up (up to 5 years)
Patient Adherence to Out-of-Hospital Nutritional Support
Evaluation of patient-reported adherence to prescribed oral nutritional supplements or enteral/parenteral support regimens after hospital discharge. Adherence data will be collected via structured interviews and compared with clinical outcomes and readmission rates.
Time frame: Baseline to 12 months post-treatment initiation
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The study intends to share IPD with other researchers for advancing scientific understanding and improving patient care. The shared data will include anonymized participant information, such as demographic details, clinical outcomes, and treatment responses. The data will be stripped of any identifiers to ensure participant confidentiality.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: The data will become available after the publication of the main study results, anticipated to be by the end of 2030. The data will be accessible for a period of five years following this date.
Access criteria: Researchers interested in accessing the data will be required to submit a proposal outlining their intended use of the data, which will be reviewed by the study's principal investigator. Access will be granted based on the scientific merit and ethical considerations of the proposal.
Started Oct 2024 (actual). Primary completion is estimated for Oct 2029, 60 months after the start.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 60 months is above that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xiaoqin Luo